A novel anticancer therapy that simultaneously targets aberrant p53 and Notch activities in tumors.
Yao Y, Wang L, Zhang H, Wang H, Zhao X, Zhang Y, Zhang L, Fan X, Qian G, Hu JF, Ge S.
Yao Y, et al. Among authors: zhang l, zhang h, zhang y.
PLoS One. 2012;7(10):e46627. doi: 10.1371/journal.pone.0046627. Epub 2012 Oct 10.
PLoS One. 2012.
PMID: 23071601
Free PMC article.